How mRNA Technology Works Beyond COVID Vaccines

Two Decades of Rejection Before a Pandemic Proved Them Right

Katalin Karikó spent the 1990s writing grant proposals for mRNA-based therapies. Nearly every one was rejected. The University of Pennsylvania demoted her in 1995 for failing to secure funding. Her collaborator Drew Weissman, an immunologist down the hall, was one of the few who saw potential. Together, in 2005, they published a paper showing that chemically modified mRNA could evade the immune system's inflammatory response—the key breakthrough that made mRNA vaccines possible. Eighteen years later, they shared the 2023 Nobel Prize in Physiology or Medicine. Their discovery had by then been injected into over 13 billion arms worldwide.

How mRNA Instructs Cells to Build Proteins

Traditional vaccines introduce a weakened pathogen or a protein fragment to train the immune system. mRNA vaccines take a fundamentally different approach: they deliver a set of molecular instructions.

• Synthetic mRNA encoding a target protein (such as the SARS-CoV-2 spike protein) is manufactured in a cell-free system
• The mRNA is encapsulated in lipid nanoparticles (LNPs)—tiny fat bubbles roughly 80-100 nanometers in diameter
• After injection, LNPs fuse with cell membranes and release mRNA into the cytoplasm
• Ribosomes read the mRNA sequence and assemble the corresponding protein
• The immune system detects the foreign protein, generates antibodies, and creates memory T and B cells
• The mRNA degrades naturally within 48-72 hours, leaving no permanent genetic material

The mRNA never enters the cell nucleus. It cannot alter DNA. This distinction matters because persistent misinformation has claimed otherwise.

The Lipid Nanoparticle Delivery System

Without lipid nanoparticles, mRNA therapy would fail. Naked mRNA injected into the body is destroyed by enzymes called RNases within minutes. The LNP serves as both shield and delivery vehicle.

The ionizable lipid is the most critical and proprietary component. At neutral pH in the bloodstream, it carries no charge—helping the particle avoid immune detection. Inside the acidic environment of the endosome (pH ~5), it becomes positively charged, destabilizing the endosomal membrane and releasing the mRNA cargo into the cytoplasm. Different ionizable lipid formulations are a major source of competitive advantage between Moderna and BioNTech.

The Cold Chain Challenge

Early mRNA vaccines required ultra-cold storage. The Pfizer-BioNTech COVID vaccine initially needed -70 degrees Celsius. Moderna's formulation was more stable at -20 degrees Celsius, and later versions could be stored at standard refrigerator temperatures for up to 30 days. This mattered enormously for global distribution.

The instability stems from the mRNA molecule itself. Even with chemical modifications—particularly the substitution of uridine with N1-methylpseudouridine, the Karikó-Weissman innovation—mRNA remains fragile compared to protein-based vaccines. Next-generation formulations aim for room-temperature stability through lyophilization (freeze-drying) and novel LNP compositions.

Cancer Vaccines: The Next Frontier

The most ambitious application of mRNA technology is personalized cancer vaccines. Unlike infectious disease vaccines that target a known pathogen, cancer vaccines must target mutations unique to each patient's tumor.

The personalized approach works like this: surgeons remove a tumor sample, sequence its DNA, identify mutations not present in the patient's healthy tissue, and manufacture an mRNA vaccine encoding those specific neoantigens—all within approximately six weeks. The vaccine trains the immune system to recognize and attack cells carrying those mutations.

The melanoma results are the most mature. Moderna's Phase III trial combining its personalized cancer vaccine with Merck's checkpoint inhibitor Keytruda showed a 44% reduction in recurrence or death compared to Keytruda alone. If confirmed, it would represent the first successful personalized cancer vaccine.

The Broader Pipeline: Flu, RSV, and Beyond

COVID proved the platform works. Companies are now racing to apply it across infectious diseases.

• Influenza: Moderna's mRNA-1010 targets four flu strains simultaneously; Phase III trials showed non-inferior immune responses to traditional flu vaccines
• RSV: mRNA-1345 received FDA approval in 2024 for adults over 60, the first mRNA vaccine approved beyond COVID
• HIV: Multiple candidates in Phase I using mRNA to present stabilized HIV envelope proteins; results are preliminary
• Nipah virus: No approved vaccine exists; mRNA candidates entered Phase I trials in 2024
• Combination vaccines: Moderna is developing a single-shot flu + COVID combination vaccine to simplify annual boosters

Manufacturing Speed: The Strategic Advantage

Perhaps the most transformative feature of mRNA technology is manufacturing speed. Traditional vaccine development takes 10-15 years. The Moderna COVID vaccine sequence was designed within two days of receiving the SARS-CoV-2 genetic sequence in January 2020. Clinical-grade doses were shipped for Phase I trials within 42 days.

This speed comes from the platform nature of the technology. The manufacturing process is identical regardless of the target protein—only the mRNA sequence changes. A facility producing an influenza mRNA vaccine can pivot to a pandemic pathogen within weeks by simply swapping the genetic template. That capability transforms pandemic preparedness from a reactive scramble into a programmable response.

The limiting factor is no longer science. It is regulatory approval timelines, public trust, and the economics of reaching low-income countries where the disease burden is highest and purchasing power is lowest.

This article is for informational purposes only. Consult a qualified professional for medical decisions.